CN110382001A - 化脓性汗腺炎的治疗 - Google Patents

化脓性汗腺炎的治疗 Download PDF

Info

Publication number
CN110382001A
CN110382001A CN201880016408.4A CN201880016408A CN110382001A CN 110382001 A CN110382001 A CN 110382001A CN 201880016408 A CN201880016408 A CN 201880016408A CN 110382001 A CN110382001 A CN 110382001A
Authority
CN
China
Prior art keywords
subject
patients
mabpl
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880016408.4A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦利·A·金
埃万盖洛斯·J·伽马雷洛斯-博尔布里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
XBIOTECH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XBIOTECH Inc filed Critical XBIOTECH Inc
Publication of CN110382001A publication Critical patent/CN110382001A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201880016408.4A 2017-02-16 2018-02-16 化脓性汗腺炎的治疗 Pending CN110382001A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762459841P 2017-02-16 2017-02-16
US62/459,841 2017-02-16
PCT/IB2018/000209 WO2018150265A1 (en) 2017-02-16 2018-02-16 Treatment of hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
CN110382001A true CN110382001A (zh) 2019-10-25

Family

ID=63170129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880016408.4A Pending CN110382001A (zh) 2017-02-16 2018-02-16 化脓性汗腺炎的治疗

Country Status (12)

Country Link
US (5) US11225517B2 (https=)
EP (1) EP3582813A4 (https=)
JP (2) JP7145162B2 (https=)
KR (1) KR20190117579A (https=)
CN (1) CN110382001A (https=)
AU (1) AU2018220862A1 (https=)
CA (1) CA3053231A1 (https=)
IL (1) IL268569A (https=)
MX (1) MX2019009798A (https=)
PH (1) PH12019501900A1 (https=)
SG (1) SG11201907159SA (https=)
WO (1) WO2018150265A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702023A (zh) * 2020-04-16 2023-02-14 詹森生物科技公司 化脓性汗腺炎的治疗

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
TWI737000B (zh) * 2018-10-22 2021-08-21 美商美國禮來大藥廠 用於治療化膿性汗腺炎之泛-ｅｌｒ＋ｃｘｃ趨化介素抗體
CN113905760A (zh) * 2019-02-28 2022-01-07 詹森生物科技公司 用于治疗化脓性汗腺炎的抗IL-α抗体
WO2021048736A1 (en) 2019-09-11 2021-03-18 Pfizer Inc. Treatment of hidradenitis with jak inhibitors
JP2025509615A (ja) * 2022-03-17 2025-04-11 ファイザー・インコーポレイテッド 汗腺炎を治療するための方法、投与計画、および組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103079594A (zh) * 2010-06-03 2013-05-01 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
CN103476933A (zh) * 2011-03-14 2013-12-25 塞罗多斯公司 白介素1受体的拮抗剂
WO2014055541A1 (en) * 2012-10-04 2014-04-10 Xbiotech, Inc. Treatment of psychiatric conditions
US20160024190A1 (en) * 2013-03-12 2016-01-28 Zenyaku Kogyo Kabushikikaisha Anti-staphylococcus antibody, method for manufacturing same, and usage of same

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5407431A (en) 1989-07-11 1995-04-18 Med-Design Inc. Intravenous catheter insertion device with retractable needle
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
CA2147151A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Therapeutic and diagnostic imaging compositions and methods
ES2159529T5 (es) 1993-03-05 2011-03-09 Bayer Corporation Anticuerpos monoclonales humanos anti-tnf alfa.
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
DE19943790C2 (de) 1999-09-13 2001-11-15 Ericsson Telefon Ab L M Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten
US6380129B1 (en) 1999-11-02 2002-04-30 Richard J. Kraemer Enhanced materials for treatment of contamination
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Ｖｐｌｆの活性を阻害する抗体
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7030126B2 (en) 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
KR100493102B1 (ko) 2003-06-30 2005-06-02 삼성전자주식회사 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
EP1750746A1 (en) * 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
DK1915620T3 (da) 2005-08-02 2010-10-04 Xbiotech Inc Diagnose, behandling og prævention af vaskulære sygdomme ved hjælp af IL-1alpha-autoantistoffer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
CN101267834B (zh) 2005-09-28 2013-06-05 赛托斯生物技术公司 白介素-1偶联物及其用途
BRPI0709977A2 (pt) 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
WO2007132338A2 (en) 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
CN102580086A (zh) 2006-05-22 2012-07-18 埃克斯生物科技公司 使用抗IL-1α抗体治疗癌症
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
FR2902659A1 (fr) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
WO2009128934A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
AU2009291536B2 (en) 2008-09-12 2012-08-16 Xbiotech Inc. Targeting pathogenic monocytes
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
SG172855A1 (en) 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
IN2012DN02634A (https=) 2009-10-15 2015-09-04 Abbvie Inc
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
JP5866130B2 (ja) 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
PH12016502073B1 (en) * 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN113018431A (zh) 2012-10-04 2021-06-25 詹森生物科技公司 治疗血管疾病及其并发症
US20150024031A1 (en) 2013-07-17 2015-01-22 Baxter International Inc. Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent
KR101753553B1 (ko) 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103079594A (zh) * 2010-06-03 2013-05-01 阿布维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
CN103476933A (zh) * 2011-03-14 2013-12-25 塞罗多斯公司 白介素1受体的拮抗剂
WO2014055541A1 (en) * 2012-10-04 2014-04-10 Xbiotech, Inc. Treatment of psychiatric conditions
US20160024190A1 (en) * 2013-03-12 2016-01-28 Zenyaku Kogyo Kabushikikaisha Anti-staphylococcus antibody, method for manufacturing same, and usage of same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EVANGELOS J. GIAMARELLOS-BOURBOULIS等: "MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB", 《CLINICALTRIALS.GOV》 *
VASSILIKI TZANETAKOU等: "Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa A Randomized Clinical Trial", 《JAMA DERMATOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115702023A (zh) * 2020-04-16 2023-02-14 詹森生物科技公司 化脓性汗腺炎的治疗

Also Published As

Publication number Publication date
JP2020507587A (ja) 2020-03-12
US20190389946A1 (en) 2019-12-26
EP3582813A1 (en) 2019-12-25
IL268569A (en) 2019-09-26
US11225517B2 (en) 2022-01-18
PH12019501900A1 (en) 2019-10-21
SG11201907159SA (en) 2019-09-27
WO2018150265A1 (en) 2018-08-23
RU2019127384A3 (https=) 2021-06-04
US20180230211A1 (en) 2018-08-16
AU2018220862A1 (en) 2019-08-29
MX2019009798A (es) 2020-01-30
US20210179704A1 (en) 2021-06-17
EP3582813A4 (en) 2020-12-30
CA3053231A1 (en) 2018-08-23
JP7145162B2 (ja) 2022-09-30
KR20190117579A (ko) 2019-10-16
US20240025989A1 (en) 2024-01-25
JP2022188083A (ja) 2022-12-20
RU2019127384A (ru) 2021-03-16
US20220127353A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US20240025989A1 (en) Treatment of hidradenitis suppurativa
CA2825986C (en) Arthritis treatment
KR102004554B1 (ko) 피부과학적 병리의 치료
US20200277370A1 (en) Treatment of hidradenitis suppurativa
KR20170113687A (ko) 종양성 질병들에 대한 치료
US20230235042A1 (en) Treatment of hidradenitis suppurativa
JP2022530063A (ja) 抗体製剤
RU2772202C2 (ru) Лечение гнойного гидраденита
CN112912140A (zh) 用于治疗化脓性汗腺炎的pan-elr+cxc趋化因子抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Great temperature

Applicant after: XBIOTECH, Inc.

Address before: Great temperature

Applicant before: XBIOTECH, Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210121

Address after: Pennsylvania, USA

Applicant after: Janssen Biotech, Inc.

Address before: Great temperature

Applicant before: XBIOTECH, Inc.